



DC HEALTHCARE HOLDINGS BERHAD

Registration No. 202201014036 (1459733-P)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT
FOR THE SECOND QUARTER ENDED
30 JUNE 2024**

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE SECOND QUARTER ENDED 30 JUNE 2024

	Note	3-MONTH ENDED		PERIOD TO DATE	
		30.06.2024 RM'000	30.06.2023 RM'000	30.06.2024 RM'000	30.06.2023 RM'000
Revenue	A9	13,881	17,892	23,335	34,703
Cost of sales		(8,689)	(7,294)	(16,924)	(14,336)
Gross profit		5,192	10,598	6,411	20,367
Other income		364	9	637	69
Staff costs		(2,378)	(1,986)	(5,422)	(4,556)
Administrative expenses		(9,506)	(3,055)	(15,573)	(6,754)
(Loss)/Profit from Operations		(6,328)	5,566	(13,947)	9,126
Interest expense		(383)	(295)	(673)	(670)
(Loss)/Profit before tax	B12	(6,711)	5,271	(14,620)	8,456
Taxation	B6	-	(1,254)	-	(2,082)
(Loss)/Profit after tax		(6,711)	4,017	(14,620)	6,374
(Loss)/Profit for the financial period, representing total comprehensive income for the financial period					
		(6,711)	4,017	(14,620)	6,374
(Loss)/Profit for the financial period attributable to:					
Owners of the Company		(6,711)	4,017	(14,620)	6,374
		(6,711)	4,017	(14,620)	6,374
Total comprehensive (loss)/income for the financial period attributable to:					
Owners of the Company		(6,711)	4,017	(14,620)	6,374
		(6,711)	4,017	(14,620)	6,374
(Loss)/Earning per share attributable to Owners of the Company:					
Basic/Diluted (sen) ⁽¹⁾	B11	(0.67)	0.50	(1.47)	0.80

Note

(1) The basic/ diluted earnings per share (“EPS”) or loss per share (“LPS”) is calculated based on the weighted average number of ordinary shares referred to in Note B11.

The Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2023 and the accompanying explanatory notes attached to the consolidated interim financial report.

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2024

	UNAUDITED	AUDITED
	AS AT	AS AT
	30.06.2024	31.12.2023
	RM'000	RM'000
ASSETS		
Non-current assets		
Plant and equipment	33,459	30,064
Right-of-use assets	28,590	22,938
Deferred tax assets	433	433
Total non-current assets	62,482	53,435
Current assets		
Inventories	3,851	3,782
Trade receivables	649	608
Other receivables, deposits and prepayments	5,870	10,712
Tax recoverable	586	285
Short-term funds	20,726	23,972
Fixed deposits with licensed banks	1,135	111
Cash and cash equivalents	4,384	6,260
Total current assets	37,201	45,730
TOTAL ASSETS	99,683	99,165
EQUITY AND LIABILITIES		
Equity		
Share capital	57,428	57,428
Retained earnings	1,100	15,720
Reorganization reserves	(8,764)	(8,764)
TOTAL EQUITY	49,764	64,384
Liabilities		
Non-current liabilities		
Lease liabilities	22,016	17,856
Borrowings	216	-
Provision	159	159
Deferred tax liabilities	729	455
Total non-current liabilities	23,120	18,470
Current liabilities		
Trade payables	1,408	1,207
Other payables and accruals	3,650	5,527
Contract liabilities	13,660	3,709
Lease liabilities	7,081	5,312
Borrowings	1,000	-
Tax Payable	-	556
Total current liabilities	26,799	16,311
TOTAL LIABILITIES	49,919	34,781
TOTAL EQUITY AND LIABILITIES	99,683	99,165

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2024
(CONT'D)**

	<u>UNAUDITED</u> AS AT 30.06.2024 RM'000	<u>AUDITED</u> AS AT 31.12.2023 RM'000
Weighted Average number of ordinary shares ('000)	996,300	996,300
NET ASSETS PER SHARE (RM)	<u>0.05</u>	<u>0.06</u>

The Unaudited Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2023 and the accompanying explanatory notes attached to the consolidated interim financial report.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SECOND QUARTER ENDED 30 JUNE 2024

	Note	Capital Contribution				Distributable Retained Earnings RM'000	Total Equity RM'000
		Share Capital RM'000	Invested Equity RM'000	from Former Holding Company of Reorganization Subsidiaries RM'000	Reserves RM'000		
Unaudited							
As at 1 January 2024		57,428	-	-	(8,764)	15,720	64,384
Loss net of tax, representing total comprehensive income for the financial period		-	-	-	-	(14,620)	(14,620)
As at 30 June 2024		57,428	-	-	(8,764)	1,100	49,764

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SECOND QUARTER ENDED 30 JUNE 2024 (Cont'd)

	Note	Share Capital RM'000	Invested Equity RM'000	Capital Contribution from former Holding Company of Subsidiaries RM'000	Reorganization Reserves RM'000	Distributable Retained Earnings RM'000	Total Equity RM'000
Audited							
As at 1 January 2023		1	801	1,030	-	13,216	15,048
Profit net of tax, representing total comprehensive income for the financial year		-	-	-	-	2,504	2,504
Transaction with owners:							
Effect of IPO reorganization		9,565	(801)	-	(8,764)	-	-
Repayment of capital contribution from holding company of subsidiaries		-	-	(1,030)	-	-	(1,030)
Issuance of ordinary shares		49,815	-	-	-	-	49,815
Share issuance expenses		(1,953)	-	-	-	-	(1,953)
		57,427	(801)	(1,030)	(8,764)	-	46,832
As at 31 December 2023		57,428	-	-	(8,764)	15,720	64,384

The Unaudited Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2023 and the accompanying explanatory notes attached to the consolidated interim financial report.

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE SECOND QUARTER ENDED 30 JUNE 2024

	Note	PERIOD TO DATE	
		30.06.2024 RM'000	30.06.2023 RM'000
Cash Flows From Operating Activities			
Loss /(Profit) before tax		(14,620)	8,456
Adjustments for:			
Depreciation of plant and equipment		1,861	927
Depreciation of right-of-use assets		3,206	2,676
Gain on disposal of plant and equipment		-	(9)
Property, plant and equipment write-off		1	13
Waiver of lease liabilities		(129)	(31)
Interest expense		672	670
Interest income		(45)	(19)
Operating (loss) /profit before working capital changes		(9,054)	12,683
Changes In working capital:			
Inventories		(69)	(62)
Contract liabilities		9,950	(25)
Receivables		4,802	(4,199)
Payables		(1,676)	(247)
Cash generated from operations		3,953	8,150
Interest paid		(672)	(670)
Interest received		45	19
Income tax paid		(585)	(2,018)
Net cash from operating activities		2,741	5,481
Cash Flows From Investing Activities			
Purchase of plant and equipment		(6,354)	(1,353)
Proceeds from disposal of plant and equipment		56	-
Additional of right-of-use assets		1,275	-
Net cash used in investing activities		(5,023)	(1,353)
Cash Flows From Financing Activities			
Net repayment to related company		-	(1,190)
Net repayment of lease liabilities		(3,032)	(2,789)
Net drawdown/(repayment) of loans		1,216	(305)
Net cash used in financing activities		(1,816)	(4,284)
Net decrease in cash and cash equivalents		(4,098)	(156)
Cash and cash equivalents at the beginning of the financial period		30,343	7,674
Cash and cash equivalents at the end of the financial period		26,245	7,518

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE SECOND QUARTER ENDED 30 JUNE 2024 (CONT'D)

The Unaudited Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2023 and the accompanying explanatory notes attached to the consolidated interim financial report.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

A. NOTES TO THE INTERIM FINANCIAL REPORT

A1. Basis of preparation

The interim financial report of DC Healthcare and its subsidiaries (“**Group**”) are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standards (“**MFRS**”) No. 134: Interim Financial Reporting and Rule 9.22 and Appendix 9B of the Listing Requirements of Bursa Securities.

This interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2023 as disclosed in the Annual Report 2023 and the accompanying explanatory notes attached to the consolidated interim financial report.

A2. Summary of Significant Accounting Policies

The significant accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted as disclosed in the Accountants’ Report in the Prospectus, except for the adoption of the following MFRSs, Amendments to MFRSs and new Interpretations effective for the financial periods beginning on or after 1 January 2024.

	Effective dates for financial periods beginning on or after
● Amendments to MFRS 16 <i>Lease Liability in a Sale and Leaseback</i>	1 January 2024
● Amendments to MFRS 101 <i>Non-Current Liabilities with Covenants and Classification of Liabilities as Current or Non-Current</i>	1 January 2024
● Amendments to MFRS 107 and MFRS 7 <i>Supplier Finance Arrangements</i>	1 January 2024
● Amendments to MFRS 121 <i>Lack of Exchangeability</i>	1 January 2025

Standards issued but not yet effective

	Effective dates for financial periods beginning on or after
● Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	To be announced

The Group will adopt the above accounting pronouncements when they become effective in the respective financial periods. These accounting pronouncements are not expected to have any effect to the financial statements of the Group upon their initial applications.

A. NOTES TO THE INTERIM FINANCIAL REPORT (CONT'D)

A3. Auditors' report on preceding annual financial statements

There was no qualification on the audited consolidated financial statements of the Group for the financial year ended 31 December 2023.

A4. Seasonal or cyclical factors

The business operations of the Group were not materially affected by any seasonal and cyclical effects during the current financial quarter and financial period-to-date.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and financial period-to-date.

A6. Material changes in estimates

There were no material changes in the estimates that have a material effect to the Group in the current financial quarter and financial period-to-date.

A7. Debt and equity securities

There were no issuances, cancellations, repurchases, resale and repayment of debts and equity during the current financial quarter under review.

A8. Dividends paid

There was no dividend paid during the current financial quarter under review.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

A. NOTES TO THE INTERIM FINANCIAL REPORT (CONT'D)

A9. Segmental information

The Group's segmental information as follows:

	3-MONTH ENDED		PERIOD TO DATE	
	30.06.2024	30.06.2023	30.06.2024	30.06.2023
	RM'000	RM'000	RM'000	RM'000
Aesthetic services	11,654	15,923	18,920	30,853
General medical services	1,650	1,432	3,272	2,811
Sale of skincare products	577	537	1,143	1,039
Total	13,881	17,892	23,335	34,703
Segment profit	5,192	10,598	6,411	20,367
Other income	364	9	637	69
Unallocated expenses	(11,884)	(5,041)	(20,995)	(11,310)
Finance costs	(383)	(295)	(673)	(670)
Taxation	-	(1,254)	-	(2,082)
(Loss)/Profit for the financial period	(6,711)	4,017	(14,620)	6,374

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

A. NOTES TO THE INTERIM FINANCIAL REPORT (CONT'D)

A10. Valuation of property, plant and equipment

There was no valuation of the property, plant and equipment in the current financial quarter under review.

A11. Material events subsequent to the end of the current financial quarter

There were no other material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

A12. Changes in the composition of the Group

There were no material changes in the composition of the Group for the current financial quarter under review.

A13. Contingent assets and contingent liabilities

There were no contingent assets and contingent liabilities as at the date of this interim report.

A14. Material capital commitments

There is no material commitment for capital expenditure, which upon becoming enforceable, may have a material effect on the Group's financial position as at the date of this interim financial report.

A15. Significant related party transactions

There were no significant related party transactions during the current financial quarter under review.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

B1. Review of Performance

(a) Results for current quarter

	3-MONTH ENDED			
	30.06.2024	30.06.2023	Changes	
	RM'000	RM'000	RM'000	%
Revenue	13,881	17,892	(4,011)	-22%
(Loss)/Profit before tax	(6,711)	5,271	(11,982)	-227%

The Group recorded revenue of RM13.88 million for the current financial quarter ended 30 June 2024 which represented a decrease of RM4.01 million or 22% as compared to the recorded revenue of RM17.89 million for the preceding year corresponding quarter ended 30 June 2023.

The Group's revenue was principally derived from the aesthetic segment which contributed RM11.66 million or 84% of the total revenue for the current financial quarter ended 30 June 2024. This represented a decrease in revenue from the aesthetic segment of 27% as compared to the preceding year corresponding quarter ended 30 June 2023 of RM15.92 million, mainly due to the lower redemption rate in aesthetic services. Despite this lower redemption rate, the Group's contract liabilities have increased to RM13.66 million as at 30 June 2024, and cash sales collection remained healthy.

The Group recorded loss before tax of RM6.71 million for the current financial quarter ended 30 June 2024 compared to profit before tax of RM5.27 million for the preceding year corresponding quarter ended 30 June 2023. The loss before tax in the current financial quarter under review mainly attributable to decrease in gross profit and higher administrative expenses of approximately RM9.51 million, mainly caused by increase in marketing costs by RM1.64 million, increase in operation and maintenance cost by RM1.87 million, increase in depreciation of plant and equipment and right-of-use assets by RM1.10 million and a non-recurring professional fee of RM1.39 million in relations to corporate exercises which were expensed off in the current financial quarter under review as compared to the preceding year corresponding quarter. Save for the non-recurring professional fee, the increased in administrative expenses aligned with the growth in the number of aesthetic outlets (12 outlets in Q2 2023: 17 outlets in Q2 2024), the establishment of new products under Ten Doctors, and the opening of four new outlets (nil in Q2 2023) for slimming services. Hence, in total 21 outlets opened in Q2 2024 as compared to 12 in Q2 2023.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (Cont'd)

B1. Review of Performance (Cont'd)

(b) Results for financial period-to-date

	PERIOD TO DATE			
	30.06.2024 RM'000	30.06.2023 RM'000	Changes RM'000	%
Revenue	23,335	34,703	(11,368)	-33%
(Loss)/Profit before tax	(14,620)	8,456	(23,076)	-273%

The Group recorded revenue of RM23.34 million for the current financial quarter ended 30 June 2024 which represented a decrease of RM11.37 million or 33% as compared to the recorded revenue of RM34.70 million for the preceding year corresponding quarter ended 30 June 2023.

The Group's revenue was principally derived from the aesthetic segment which contributed RM18.92 million or 81% of the total revenue for the current financial quarter ended 30 June 2024. This represented a decrease in revenue from the aesthetic segment of 39% as compared to the preceding year corresponding quarter ended 30 June 2023 of RM30.85 million, mainly due to the lower redemption rate in aesthetic services. Despite having lower redemption rate in the current financial quarter under review, the Group's cash sales collection remained healthy.

The Group recorded loss before tax of RM14.62 million for the current financial quarter ended 30 June 2024 compared to profit before tax of RM8.46 million for the preceding year corresponding quarter ended 30 June 2023. The decline is primarily attributed to a significant reduction in gross profit. Additionally, the Group faced higher administrative expenses, which approximately RM15.57 million for the current financial quarter ended 30 June 2024. This significant increase was driven by several factors:

- **Marketing Costs:** These rose by RM3.31 million, reflecting the Group's increased efforts to promote its services and products.
- **Operation and Maintenance Costs:** There was an increase of RM2.27 million, mainly due to the expansion of the Group's operations.
- **Depreciation:** Depreciation of plant and equipment, as well as right-of-use assets, saw a rise of RM1.39 million.
- **Professional Fees:** A non-recurring professional fee of RM1.39 million was incurred in relation to corporate exercises.

Excluding the non-recurring professional fee, the rise in administrative expenses aligns with the Group's strategic growth initiatives, including the expansion of aesthetic outlets from 12 in Q2 2023 to 17 in Q2 2024. In addition, the Group introduced new products under the Ten Doctors brand and opened four new outlets (nil in Q2 2023) for slimming services, further contributing to the increased costs. Hence, in total 21 outlets opened in Q2 2024 as compared to 12 in Q2 2023.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (Cont'd)**B2. Comparison with immediate preceding quarter's results**

	3-MONTH ENDED			
	Current	Preceding		
	Quarter	Quarter		
	30.06.2024	31.03.2024	Changes	
	RM'000	RM'000	RM'000	%
Revenue	13,881	9,454	4,427	47%
Loss before tax	(6,711)	(7,909)	1,198	15%

The Group's revenue for the current financial quarter has increased by RM4.43 million or 47% to RM13.88 million from RM9.45 million as compared to the immediate preceding quarter mainly due to the higher number of treatments provided in aesthetic services. The higher revenue had translated into a higher gross profit to RM5.19 million in the current financial quarter under review from RM1.22 million for the immediate preceding financial quarter ended 31 March 2024. However, the higher gross profit was offset by higher marketing fee by RM0.47 million, higher depreciation of plant and equipment and right-of-use assets by RM0.34 million and a non-recurring professional fee of RM1.39 million in relations to corporate exercises the current financial period under review.

Consequently, the Group recorded a lower loss before tax of RM6.71 million for the current financial quarter ended 30 June 2024, representing a decrease in loss before tax of RM1.20 million from RM7.91 million for the immediate preceding financial quarter ended 31 March 2024.

B3. Prospects

The Group's strategies are to continue to focus on its core business in light of the growth in the medical aesthetic by implementing the following business strategies: -

- (i) To continue expanding our existing clinics by establishing new medical aesthetic clinics in the Southern & Northern regions.
- (ii) In order to support the expansion, we intend to strengthen our medical doctors, clinic consultants and other support staff by attracting and recruiting highly skilled and experienced personnel.
- (iii) Our Group is to continuously upgrading the technology of our medical equipment to the latest in order to enhance our services offering and also in support of our expansion plans.

The Group believes that its prospects in the medical aesthetic service industry are favourable in view of our competitive strengths.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B4. Profit Forecast or Profit Guarantee

The Group did not issue any profit forecast or profit guarantee during the current financial quarter under review.

B5. Status of corporate proposals

Save as disclosed below, there were no corporate proposals announced but not completed as at the date of this interim report.

I. Variation for the Utilisation of Proceeds from the IPO

On 6 November 2023, the Company announced that it has varied RM2.36 million of the IPO Proceeds initially allocated for the setting up of new aesthetic medical clinics to be located in Nilai (Negeri Sembilan) and Bukit Mertajam (Pulau Pinang) to set up at Publika Shopping Gallery (Kuala Lumpur) and Juru Auto City (Pulau Pinang) (“**First Variation**”)

On 16 July 2024, the Company announced that it proposed to reallocate RM2.36 million of the IPO proceeds initially allocated for the setting up of new aesthetic medical clinics to be located at Bayan Lepas (Pulau Pinang) and Sungai Petani (Kedah) to be set up at Georgetown (Pulau Pinang) and Kota Kinabalu (Sabah) respectively. (“**Proposed Second Variation**”).

The targeted locations of the new aesthetic medical clinics after the Proposed Second Variation are as follows:

No.	Original utilization as disclosed in the Prospectus dated 27 June 2023	Targeted locations after the First Variation announced on 6 November 2023	Proposed Second Variation
1.	Taman Molek, Johor	Taman Molek, Johor	Taman Molek, Johor
2.	Pelanggi, Johor	Pelanggi, Johor	Pelanggi, Johor
3.	Taman Melaka Raya, Melaka	Taman Melaka Raya, Melaka	Taman Melaka Raya, Melaka
4.	Nilai, Negeri Sembilan	-	-
5.	Bukit Mertajam, Pulau Pinang	-	-
6.	Bayan Lepas, Pulau Pinang	Bayan Lepas, Pulau Pinang	-
7.	Ipoh, Perak	Ipoh, Perak	Ipoh, Perak
8.	Sungai Petani, Kedah	Sungai Petani, Kedah	-
9.	-	Publika Shopping Gallery, Kuala Lumpur	Publika Shopping Gallery, Kuala Lumpur
10.	-	Juru Auto City, Pulau Pinang	Juru Auto City, Pulau Pinang
11.	-	-	Georgetown, Pulau Pinang
12.	-	-	Kota Kinabalu, Sabah

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B6. Income tax expenses

	3-MONTH ENDED		PERIOD TO DATE	
	30.06.2024	30.06.2023	30.06.2024	30.06.2023
	RM'000	RM'000	RM'000	RM'000
Taxation	-	1,254	-	2,082
Total Taxation	-	1,254	-	2,082

B7. Utilisation of Proceeds from the IPO

The gross proceeds arising from the public issue amounting to RM49.82 million is intended to be utilised in the following manner: -

Description of utilisation	Proposed	Actual	Balance	Estimated timeframe for Utilisation upon Listing
	Utilisation	Utilisation	Utilisation	
	RM'000	RM'000	RM'000	
Establishing new aesthetic medical clinics	9,440	5,699	3,741	Within 18 months
Purchase of new medical machines and equipment	13,124	7,577	5,547	Within 18 months
Repayment of borrowings	6,238	6,238	-	Within 6 months
Working capital	17,013	6,034	10,979	Within 36 months
Listing expenses	4,000	4,000	-	Within 1 month
Total	49,815	29,548	20,267	

B8. Bank borrowings

The Group's bank borrowings were as follows:

	UNAUDITED	AUDITED
	30.06.2024	31.12.2023
	RM'000	RM'000
Current		
Hire purchase	1,226	408
Overdraft	1,000	-
	<u>2,226</u>	<u>408</u>
Non Current		
Hire purchase	3,570	1,595
Term loan	216	-
	<u>3,786</u>	<u>1,595</u>
Total	<u>6,012</u>	<u>2,003</u>

All the Group's bank borrowings are denominated in Ringgit Malaysia.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B9. Material litigation

There was no material litigation involving the Group as at 30 June 2024.

B10. Dividend

No dividend has been declared or proposed for the current financial quarter under review.

B11. Earnings/(Loss) per share

The basic/ diluted loss per share (“LPS”) or earnings per share (“EPS”) is calculated by dividing the (loss)/profit for the period attributable to owners of the Company by weighted average number of ordinary shares of the Company during the financial period as follows:

	3-MONTH ENDED		PERIOD TO DATE	
	30.06.2024	30.06.2023	30.06.2024	30.06.2023
	RM'000	RM'000	RM'000	RM'000
(Loss)/Profit after tax attributable to Owners of the Company (RM'000)	(6,711)	4,017	(14,620)	6,374
Number of ordinary shares ('000) ⁽¹⁾⁽²⁾	996,300	797,040	996,300	797,040
Basic/Diluted (LPS)/EPS (sen)	(0.67)	0.50	(1.47)	0.80

Notes:

- 1) Based on the number of issued share capital of 996,300,000 ordinary shares after the completion of the IPO reorganisation and the Public Issue.
- 2) Based on the number of issued share capital of 797,039,707 ordinary shares after the completion of the IPO reorganisation but before the Public Issue.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B12. Disclosure on selected expense/income items as required by the Listing Requirements

(Loss)/Profit before tax is arrived after charging/(crediting):

	3-MONTH ENDED		PERIOD TO DATE	
	30.06.2024	30.06.2023	30.06.2024	30.06.2023
	RM'000	RM'000	RM'000	RM'000
Depreciation of plant and equipment	997	655	1,861	927
Depreciation of right-of-use assets	1,742	1,323	3,206	2,676
Interest income	(40)	-	(45)	(19)
Interest expense	382	295	672	670
Gain on disposal of plant and equipment	-	-	-	(9)
	<u>3,081</u>	<u>2,273</u>	<u>5,694</u>	<u>4,245</u>

Other disclosure items pursuant to Appendix 9B, Note 16 of the Listing Requirements of Bursa Securities are not applicable.

B13. Approval of Interim Financial Report

The interim financial report as set out above was approved by the Board of Directors in accordance with a resolution dated 27 August 2024.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK